Kenvue Inc. $KVUE Shares Newly Bought by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. bought a new stake in Kenvue Inc. (NYSE:KVUE) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 614,092 shares of the company’s stock, valued at approximately $10,845,000.

Other large investors have also modified their holdings of the company. Johnson Financial Group Inc. purchased a new position in Kenvue in the second quarter valued at approximately $26,000. GK Wealth Management LLC acquired a new position in Kenvue during the third quarter worth about $27,000. CoreCap Advisors LLC boosted its position in Kenvue by 64.9% during the second quarter. CoreCap Advisors LLC now owns 1,502 shares of the company’s stock worth $29,000 after purchasing an additional 591 shares in the last quarter. Bell Investment Advisors Inc purchased a new position in shares of Kenvue during the 2nd quarter worth approximately $35,000. Finally, Keating Financial Advisory Services Inc. acquired a new stake in shares of Kenvue during the second quarter valued at $38,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

KVUE has been the subject of a number of research reports. Weiss Ratings reiterated a “hold (c)” rating on shares of Kenvue in a report on Friday, September 11th. Wall Street Zen cut Kenvue from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Barclays lifted their price objective on shares of Kenvue from $18.00 to $19.00 and gave the company an “equal weight” rating in a research note on Tuesday, July 21st. UBS Group raised their price target on shares of Kenvue from $19.00 to $20.00 and gave the company a “neutral” rating in a report on Monday. Finally, HSBC cut their price objective on shares of Kenvue from $20.00 to $19.00 and set a “hold” rating on the stock in a report on Monday, August 10th. Ten investment analysts have rated the stock with a Hold rating. Based on data from MarketBeat, Kenvue currently has an average rating of “Hold” and a consensus price target of $19.29.

Kenvue Stock Performance

NYSE:KVUE opened at $19.31 on Thursday. The company has a 50-day moving average of $18.41 and a 200-day moving average of $18.22. The firm has a market cap of $37.09 billion, a price-to-earnings ratio of 21.94, a price-to-earnings-growth ratio of 1.77 and a beta of 0.48. The company has a current ratio of 1.01, a quick ratio of 0.71 and a debt-to-equity ratio of 0.67. Kenvue Inc. has a twelve month low of $14.06 and a twelve month high of $20.13.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Friday, October 30th. The company reported $0.29 EPS for the quarter, meeting analysts’ consensus estimates of $0.29. The company had revenue of $3.89 billion during the quarter, compared to the consensus estimate of $3.86 billion. Kenvue had a return on equity of 21.22% and a net margin of 10.76%. The company’s quarterly revenue was up 3.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.28 EPS. Analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, October 2nd. Investors of record on Monday, September 21st were paid a $0.21 dividend. This represents a $0.84 dividend on an annualized basis and a dividend yield of 4.4%. The ex-dividend date of this dividend was Monday, September 21st. Kenvue’s dividend payout ratio (DPR) is presently 95.45%.

Kenvue Company Profile

Kenvue Inc is a consumer health company that develops, markets and sells products designed to support everyday health and personal care. Its portfolio spans over-the-counter medicines, skin health and beauty, and essential health products, serving consumers through retail, e-commerce and other distribution channels.

The company’s brands include Tylenol, Motrin, Zyrtec and Benadryl in self-care; Neutrogena, Aveeno and Clean & Clear in skin health and beauty; and Listerine, Johnson’s and OGX in oral care, baby care and hair care.